JHVEPhoto Broadcom ( AVGO ) was in focus on Thursday after the semiconductor and software company reported second-quarter results and guidance. And while investors may be concerned Broadcom did not lift its outlook for artificial intelligence-related sales for the rest of the year, Wall Street still sees a bright future for the Hock Tan-led company. Shares fell 15% in premarket trading, dragging d...
JHVEPhoto Broadcom ( AVGO ) was in focus on Thursday after the semiconductor and software company reported second-quarter results and guidance. And while investors may be concerned Broadcom did not lift its outlook for artificial intelligence-related sales for the rest of the year, Wall Street still sees a bright future for the Hock Tan-led company. Shares fell 15% in premarket trading, dragging down other chipmakers, such as Intel ( INTC ), Nvidia ( NVDA ), and AMD ( AMD ). Bernstein analyst Stacy Rasgon pointed out that AI revenue can be “lumpy,” but given that they're expected to be up 200% year-over-year in the coming quarter and $100B next year, it's impressive nonetheless. “While 2027 appears 2H-weighted as multiple programs ramp, this also suggesting a potentially materially higher run-rate into 2028, accompanied by stronger baseline growth from the non-AI businesses (SW, other semis) in the meantime,” Rasgon wrote in a note to clients. “And while we get the complaints on (slightly) declining gross margins as AI ASICs ramp, operating leverage is clearly offsetting (and we feel bad complaining about gross margins that remain well into the 70s anyway...) We suspect the shares may take a pause for the next couple of quarters. But the story gets interesting again once we enter 2027. And at the end of the day, we have a company growing revenues and EPS >50%, with gross/operating margins in the 70s/60s, and potentially trading at a teens P/FE in an environment that is only getting stronger. If we have to wait a quarter or two for that story to re-emerge that’s OK, we’ll wait for it.” Rasgon reiterated his Outperform rating on Broadcom and raised his price target to $550 from $525. Goldman Sachs analyst James Schneider said he would be “aggressive buyers” of the stock for several reasons, given the sharp reaction to the results and guidance. “We remain bullish on the stock at current levels as our confidence on Broadcom’s growth in 2027 and beyond is underpinned by ...
JHVEPhoto Broadcom ( AVGO ) was in focus on Thursday after the semiconductor and software company reported second-quarter results and guidance. And while investors may be concerned Broadcom did not lift its outlook for artificial intelligence-related sales for the rest of the year, Wall Street still sees a bright future for the Hock Tan-led company. Shares fell 15% in premarket trading, dragging d...
JHVEPhoto Broadcom ( AVGO ) was in focus on Thursday after the semiconductor and software company reported second-quarter results and guidance. And while investors may be concerned Broadcom did not lift its outlook for artificial intelligence-related sales for the rest of the year, Wall Street still sees a bright future for the Hock Tan-led company. Shares fell 15% in premarket trading, dragging down other chipmakers, such as Intel ( INTC ), Nvidia ( NVDA ), and AMD ( AMD ). Bernstein analyst Stacy Rasgon pointed out that AI revenue can be “lumpy,” but given that they're expected to be up 200% year-over-year in the coming quarter and $100B next year, it's impressive nonetheless. “While 2027 appears 2H-weighted as multiple programs ramp, this also suggesting a potentially materially higher run-rate into 2028, accompanied by stronger baseline growth from the non-AI businesses (SW, other semis) in the meantime,” Rasgon wrote in a note to clients. “And while we get the complaints on (slightly) declining gross margins as AI ASICs ramp, operating leverage is clearly offsetting (and we feel bad complaining about gross margins that remain well into the 70s anyway...) We suspect the shares may take a pause for the next couple of quarters. But the story gets interesting again once we enter 2027. And at the end of the day, we have a company growing revenues and EPS >50%, with gross/operating margins in the 70s/60s, and potentially trading at a teens P/FE in an environment that is only getting stronger. If we have to wait a quarter or two for that story to re-emerge that’s OK, we’ll wait for it.” Rasgon reiterated his Outperform rating on Broadcom and raised his price target to $550 from $525. Goldman Sachs analyst James Schneider said he would be “aggressive buyers” of the stock for several reasons, given the sharp reaction to the results and guidance. “We remain bullish on the stock at current levels as our confidence on Broadcom’s growth in 2027 and beyond is underpinned by ...
Exclusive: New loopholes for developers will exacerbate extreme environmental disparities, charity coalition warns The poorest and most nature-deprived communities in England will be further left behind in their access to green spaces if proposed changes to planning laws go ahead, a report finds. More than 7.4 million people in England live in areas completely devoid of immediate biodiversity, inc...
Exclusive: New loopholes for developers will exacerbate extreme environmental disparities, charity coalition warns The poorest and most nature-deprived communities in England will be further left behind in their access to green spaces if proposed changes to planning laws go ahead, a report finds. More than 7.4 million people in England live in areas completely devoid of immediate biodiversity, including 1.42 million children under 15, the report commissioned by a number of wildlife and environmental NGOs says. Continue reading...
Trevor Williams/DigitalVision via Getty Images From biotech to orbital infrastructure, the 2026 technology story is being written across industries. Five VanEck ETFs offer targeted exposure to each distinct theme. The Tech Landscape in 2026: What Has Changed Technology is no longer just a software story. As AI moves deeper into the economy, the companies enabling it now span semiconductors, roboti...
Trevor Williams/DigitalVision via Getty Images From biotech to orbital infrastructure, the 2026 technology story is being written across industries. Five VanEck ETFs offer targeted exposure to each distinct theme. The Tech Landscape in 2026: What Has Changed Technology is no longer just a software story. As AI moves deeper into the economy, the companies enabling it now span semiconductors, robotics, electrification, gaming, space and biotech. Compute capacity depends on chips and advanced manufacturing, automation relies on sensors and industrial control systems, and space infrastructure is becoming a new layer for communications and data. The 2026 technology landscape is not being shaped by one company or subsector. Innovation is spreading across the industries and systems that support the next phase of growth. Five Tech Companies to Watch Across VanEck ETFs Tech Theme VanEck ETF Featured Company What It Represents Biotechnology VanEck Biotech ETF ( BBH ) Gilead Sciences Therapies across virology, oncology and precision medicine Gaming & Digital Entertainment VanEck Video Gaming and eSports ETF ( ESPO ) NetEase Interactive entertainment and online engagement Space Infrastructure VanEck Space ETF ( WARP ) Rocket Lab Launch, satellites, and orbital data Robotics & Automation VanEck Robotics ETF ( IBOT ) ABB Industrial automation, robotics, and electrification Semiconductors VanEck Semiconductor ETF ( SMH ) NVIDIA AI compute and chip infrastructure Click to enlarge 1. Gilead Sciences Inc. ( GILD ) ETF exposure: Top holding in BBH at 14.25% of net assets as of 05/21/2026. What They Do: Gilead Sciences is a global biopharmaceutical company with a portfolio spanning HIV, liver disease, oncology and inflammation. From a technology perspective, Gilead represents the life sciences side of innovation: using molecular biology, clinical data and advanced drug development to create therapies for complex diseases. 2026 Watch Point: The biotech opportunity is increasingly tied t...
AN2 Therapeutics ( ANTX ) added ~7% in the premarket on Thursday after posting results from two early-stage studies evaluating AN2-502998, its experimental therapy for a parasitic infection known as Chagas disease (American trypanosomiasis). The Menlo Park, California-based biopharma said that the results, including data from a Phase 1 trial, supported its decision to advance AN2-502998 into mid-s...
AN2 Therapeutics ( ANTX ) added ~7% in the premarket on Thursday after posting results from two early-stage studies evaluating AN2-502998, its experimental therapy for a parasitic infection known as Chagas disease (American trypanosomiasis). The Menlo Park, California-based biopharma said that the results, including data from a Phase 1 trial, supported its decision to advance AN2-502998 into mid-stage development for chronic Chagas disease caused by the parasite T. cruzi. Citing data from a Phase 1 first-in-human trial, the company noted that trial subjects well tolerated the experimental therapy. AN2-502998 is an oral therapy designed to inhibit CPSF3, an essential enzyme involved in messenger RNA processing of T. cruzi. AN2 Therapeutics ( ANTX ) also shared data from a preclinical trial, noting that AN2-502998 led to the complete elimination of T. cruzi in non-human primates over four months after completing the therapy. In the study, NHPs with naturally acquired chronic T. cruzi infection received 28-day AN2-502998 therapy at dose levels achievable in humans. “Together, these data support our goal of making AN2-502998 the first FDA-approved therapy for chronic Chagas disease in adults,” CEO Eric Easom added. Chagas disease is estimated to affect more than 300,000 Americans. The company expects to launch a Phase 2 proof-of-concept study for AN2- 502998 later this year. More on AN2 Therapeutics AN2 Therapeutics, Inc. (ANTX) Presents at Leerink Global Healthcare Conference 2026 Transcript AN2 Therapeutics GAAP EPS of -$0.29 misses by $0.06 Seeking Alpha’s Quant Rating on AN2 Therapeutics Historical earnings data for AN2 Therapeutics Financial information for AN2 Therapeutics
Pulp Fiction director writes in Sight and Sound that ‘since the pandemic … it seems almost impossible for a new movie to come out that I don’t pick to death’ Quentin Tarantino has criticised contemporary Hollywood, calling it “a flavourless sausage factory”. Writing in Sight and Sound magazine, Tarantino said that “since the pandemic … it seems almost impossible for a new movie to come out that I ...
Pulp Fiction director writes in Sight and Sound that ‘since the pandemic … it seems almost impossible for a new movie to come out that I don’t pick to death’ Quentin Tarantino has criticised contemporary Hollywood, calling it “a flavourless sausage factory”. Writing in Sight and Sound magazine, Tarantino said that “since the pandemic … it seems almost impossible for a new movie to come out that I don’t pick to death”. He added: “Flaws, implausibilities, audience pandering, miscast performers or just plain stupid shit usually torpedoes every new movie coming out of the flavourless sausage factory that used to call itself Hollywood.” Continue reading...
Magone/iStock via Getty Images In my previous coverage of Danone published in July 2025, I focused primarily on the company's margin recovery, portfolio simplification, and the early benefits of the Renew Danone strategy. Since then, the story has evolved. While operational improvement remains important, I believe the more relevant development today is Danone's growing exposure to higher-value nut...
Magone/iStock via Getty Images In my previous coverage of Danone published in July 2025, I focused primarily on the company's margin recovery, portfolio simplification, and the early benefits of the Renew Danone strategy. Since then, the story has evolved. While operational improvement remains important, I believe the more relevant development today is Danone's growing exposure to higher-value nutrition categories through acquisitions and portfolio repositioning. That shift is the primary reason I am revisiting the stock. Danone continues to be valued as a mature business in dairy and bottled water, but the focus on earnings generation has started to move towards nutrition-related businesses. The trend of volume-driven growth is back, the importance of Specialized Nutrition has increased, and the acquisitions made have taken Danone deeper into medical nutrition, gut health, and complete nutrition. The Business Quality: A Nutrition Platform Wrapped in a Dairy Label Danone S.A. ( DANOY ) is among the biggest food and beverage companies in the world, being a leader in essential dairy & plant-based products, waters, and specialized nutrition. Some of its well-known brands include Activia, Actimel, Alpro, Oikos, Silk, Evian, Volvic, Aptamil, Nutrilon, and Nutricia. From an outside view, this looks to be just a regular portfolio of consumer staples names. The truth, however, is somewhat deeper. The driver behind this assumption is the mix. While Danone remains a prominent dairy player with an additional water and baby formula presence, it is increasingly becoming a nutrition company, with dairy remaining on the visible side while sometimes being secondary to profits. Specialized Nutrition accounts for approximately one-third of sales, and its profitability is much higher than this number would suggest. Nutrition businesses operate in a different way compared to traditional consumer staples companies. Categories such as infant formula, adult medical nutrition, or specializ...
Zhongchao ( ZCMD ) on Thursday said it will effectuate a 1-for-31 share consolidation of the company's ordinary shares of US$0.008 par value each. Beginning with the opening of trading on June 8, the company's Class A ordinary shares will begin trading on a post-share consolidation basis on Nasdaq under the same symbol "ZCMD." The objective of the share consolidation is to maintain its listing on ...
Zhongchao ( ZCMD ) on Thursday said it will effectuate a 1-for-31 share consolidation of the company's ordinary shares of US$0.008 par value each. Beginning with the opening of trading on June 8, the company's Class A ordinary shares will begin trading on a post-share consolidation basis on Nasdaq under the same symbol "ZCMD." The objective of the share consolidation is to maintain its listing on the Nasdaq Capital Market, the company said. Press release More on Zhongchao Financial information for Zhongchao
A selloff in technology stocks pushed US stocks lower before the bell on Thursday, as results from Broadcom Inc. forced an unwind in the artificial-intelligence trade that had powered gains over the last several sessions. Contracts for the Nasdaq 100 Index were down 1.3% at 8:20 a.m. in New York, putting the technology-heavy benchmark on track to extend declines. Futures for the broader S&P 500 In...
A selloff in technology stocks pushed US stocks lower before the bell on Thursday, as results from Broadcom Inc. forced an unwind in the artificial-intelligence trade that had powered gains over the last several sessions. Contracts for the Nasdaq 100 Index were down 1.3% at 8:20 a.m. in New York, putting the technology-heavy benchmark on track to extend declines. Futures for the broader S&P 500 Index dropped 0.4% . Brent crude tumbled 3.2% to around $ 95 . Broadcom shares slid 15% during the premarket session after the company delivered a disappointing forecast for AI chip revenue. While Broadcom had been making progress in pivoting to AI customers, it has come up against outsized investor expectations. “Overall, it is a good set of numbers and they are in the right place structurally with AI, but it does feel like expectations were already high,” said Ben Barringer , head of technology research at Quilter Cheviot, when speaking about Broadcom’s report. “The long-term story remains intact, but there is a bit more scrutiny now on share, mix and how sustainable that growth really is.” As a consequence, traders have been backing away from the AI trade, which has seen a resurgence in recent weeks and had provided a lift to US stocks in the last four sessions. Further fueling concerns were comments from Taiwan Semiconductor Manufacturing Co. on global chip supply falling short of AI-fueled demand. “One of the biggest risks for the AI stock market boom is its own success,” said Kathleen Brooks , research director at XTB. “The narrow breadth of this market rally is a concern, if one AI name rolls over, then the entire US stock market could come under pressure.” Iran Latest The Republican-led House voted to halt the war with Iran on Wednesday, breaking with President Donald Trump. The 215-208 vote showed worries over the war spreading in the president’s own party five months before congressional elections. The vote came after the most serious flare-up between the warring si...
Evertec (NYSE:EVTC) Executive Vice President Miguel Vizcarrondo reported the open-market purchase of 21,000 shares at around $23.37 per share on May 11, for a total value of approximately $491,000, according to an SEC Form 4 filing . Transaction value based on SEC Form 4 reported price ($23.37); post-transaction value based on May 11, 2026 market close ($23.02). Note: 1-year price change calculate...
Evertec (NYSE:EVTC) Executive Vice President Miguel Vizcarrondo reported the open-market purchase of 21,000 shares at around $23.37 per share on May 11, for a total value of approximately $491,000, according to an SEC Form 4 filing . Transaction value based on SEC Form 4 reported price ($23.37); post-transaction value based on May 11, 2026 market close ($23.02). Note: 1-year price change calculated using May 11, 2026, as the reference date. Continue reading
Blackstone Inc. limited redemptions from its flagship private credit fund for the first time after investors sought to pull 10% of the shares, the latest such fund to cap withdrawals amid a continued investor exodus. The $79 billion Blackstone Private Credit Fund told shareholders that it would return 5% of its shareholders’ money, according to a filing Thursday. During the previous quarter, the f...
Blackstone Inc. limited redemptions from its flagship private credit fund for the first time after investors sought to pull 10% of the shares, the latest such fund to cap withdrawals amid a continued investor exodus. The $79 billion Blackstone Private Credit Fund told shareholders that it would return 5% of its shareholders’ money, according to a filing Thursday. During the previous quarter, the fund allowed investors to redeem a record 7.9% after tapping senior executives to help finance the withdrawals with their own cash . Blackstone told shareholders that repurchases began to decelerate during the back end of its tender offer period. Across the $1.8 trillion private credit market, redemption requests are expected to increase this quarter as investors redouble efforts to claw back money after being restricted. This week, Cliffwater LLC capped redemptions at 5% after investors requested 17% to be returned.